Retatrutide

Description

Retatrutide is a next-generation metabolic peptide classified as a triple agonist because it activates three key hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). By engaging this broader range of receptors, Retatrutide has demonstrated greater potential for reducing body fat mass compared to earlier single- or dual-agonist therapies such as Semaglutide.

Through its multi-receptor action, Retatrutide not only enhances satiety and reduces food intake but also improves energy expenditure and metabolic balance, positioning it as a promising candidate in the field of weight management and obesity treatment.